ncRNA basic information
ncRNA ID:
MI0001150
ncRNA Database:
miRBase
ncRNA Name:
miR-196b
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
qPCR
ncRNA Target Gene:
NA
ncRNA Pathway:
PI3K/AKT pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00853 (APRD00557)
Drug Name:
Temozolomide
Drug Method:
In the present study, we explored the effects of miR-196b expression on glioma cells and characterized the relationship between miR-196b expression and the PI3K/AKT signaling pathway. We found that downregulation of miR-196b decreased the proliferation of U87 and U251 glioma cells. When anti-miR-196b and radiotherapy were used together, cellular proliferation decreased, whereas apoptosis and caspase 3/7activity, an indicator of apoptosis, increased. Meanwhile, downregulation of miR-196b remarkably inhibited glioma cell growth and colony formation when concurrent with temozolomide administration. Further studies demonstrated that neither upregulation nor downregulation of miR-196b markedly changed the protein expression levels of downstream molecules in the PI3K/AKT signaling pathway in cellular experiments. Therefore, whether miR-196b plays a role by activating the PI3K/AKT signaling pathway has not yet been determined. Together, our findings indicate that downregulation of miR-196b increased glioma cell sensitivity to temozolomide chemotherapy and radiotherapy and may be a valuable target when treating malignant gliomas.
Drug Response:
sensitive
Cancer basic information
Cancer:
glioma
Tissue/Cell:
cell line (U87 and U251)
Other information
Title:
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Journal:
Ann Clin Lab Sci
Published:
2018
PubMed ID:
30610041